TrialLeukemia2021
Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age.
Elias K Mai et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
8 papers cite it
this papercites it
TrialLeukemia2021
Elias K Mai et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.